Involvement of AChergic systems in chlordiazepoxide induced impairment of passive avoidance response

Toshitaka Nabeshima, K. Tohyama, T. Kameyama

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The chlordiazepoxide (CDP)-induced impairment of the passive avoidance response was attenuated by Ro 15-4513, a benzodiazepine inverse agonist, physostigmine and scopolamine at low doses. In a biochemical approach, CDP increased, but Ro 15-4513 decreased the acetylcholine (ACh) levels of cerebral cortex. After the training of passive avoidance, the ACh levels in the hippocampus and cerebral cortex decreased. This change disappeared by pretraining administration of CDP. These results suggest that the effect of CDP on the passive avoidance response was related to AChergic neuronal systems.

Original languageEnglish
Pages (from-to)200-206
Number of pages7
JournalNeuroscience Letters
Volume117
Issue number1-2
DOIs
Publication statusPublished - 04-09-1990
Externally publishedYes

Fingerprint

Chlordiazepoxide
Cerebral Cortex
Acetylcholine
Physostigmine
Scopolamine Hydrobromide
Benzodiazepines
Hippocampus
Ro 15-4513

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)

Cite this

@article{4c5220351e6a45feaccda08c5c781ba3,
title = "Involvement of AChergic systems in chlordiazepoxide induced impairment of passive avoidance response",
abstract = "The chlordiazepoxide (CDP)-induced impairment of the passive avoidance response was attenuated by Ro 15-4513, a benzodiazepine inverse agonist, physostigmine and scopolamine at low doses. In a biochemical approach, CDP increased, but Ro 15-4513 decreased the acetylcholine (ACh) levels of cerebral cortex. After the training of passive avoidance, the ACh levels in the hippocampus and cerebral cortex decreased. This change disappeared by pretraining administration of CDP. These results suggest that the effect of CDP on the passive avoidance response was related to AChergic neuronal systems.",
author = "Toshitaka Nabeshima and K. Tohyama and T. Kameyama",
year = "1990",
month = "9",
day = "4",
doi = "10.1016/0304-3940(90)90144-X",
language = "English",
volume = "117",
pages = "200--206",
journal = "Neuroscience Letters",
issn = "0304-3940",
publisher = "Elsevier Ireland Ltd",
number = "1-2",

}

Involvement of AChergic systems in chlordiazepoxide induced impairment of passive avoidance response. / Nabeshima, Toshitaka; Tohyama, K.; Kameyama, T.

In: Neuroscience Letters, Vol. 117, No. 1-2, 04.09.1990, p. 200-206.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Involvement of AChergic systems in chlordiazepoxide induced impairment of passive avoidance response

AU - Nabeshima, Toshitaka

AU - Tohyama, K.

AU - Kameyama, T.

PY - 1990/9/4

Y1 - 1990/9/4

N2 - The chlordiazepoxide (CDP)-induced impairment of the passive avoidance response was attenuated by Ro 15-4513, a benzodiazepine inverse agonist, physostigmine and scopolamine at low doses. In a biochemical approach, CDP increased, but Ro 15-4513 decreased the acetylcholine (ACh) levels of cerebral cortex. After the training of passive avoidance, the ACh levels in the hippocampus and cerebral cortex decreased. This change disappeared by pretraining administration of CDP. These results suggest that the effect of CDP on the passive avoidance response was related to AChergic neuronal systems.

AB - The chlordiazepoxide (CDP)-induced impairment of the passive avoidance response was attenuated by Ro 15-4513, a benzodiazepine inverse agonist, physostigmine and scopolamine at low doses. In a biochemical approach, CDP increased, but Ro 15-4513 decreased the acetylcholine (ACh) levels of cerebral cortex. After the training of passive avoidance, the ACh levels in the hippocampus and cerebral cortex decreased. This change disappeared by pretraining administration of CDP. These results suggest that the effect of CDP on the passive avoidance response was related to AChergic neuronal systems.

UR - http://www.scopus.com/inward/record.url?scp=0025183619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025183619&partnerID=8YFLogxK

U2 - 10.1016/0304-3940(90)90144-X

DO - 10.1016/0304-3940(90)90144-X

M3 - Article

C2 - 2290617

AN - SCOPUS:0025183619

VL - 117

SP - 200

EP - 206

JO - Neuroscience Letters

JF - Neuroscience Letters

SN - 0304-3940

IS - 1-2

ER -